P3.04-24 EMPOWER-Lung 2: Cemiplimab and Ipilimumab ± Chemotherapy vs Pembrolizumab in Advanced NSCLC With PD-L1 ≥50%, a Phase 3 Study

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.1731
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV